PHIA Koninklijke Philips N.V.

Philips partners with Orbita to develop conversational voice and chatbot applications to complement its telehealth solutions

Philips partners with Orbita to develop conversational voice and chatbot applications to complement its telehealth solutions

March 29, 2021

Partnership to create AI-based virtual assistants with the human touch needed for effective remote patient engagement

Amsterdam, the Netherlands and Boston, U.S. – (NYSE: PHG, AEX: PHIA), a global leader in health technology, and , an innovative provider of conversational artificial intelligence (AI) solutions for healthcare, today announced a partnership agreement to co-create next-generation conversational virtual assistants for Philips’ consumer health and patient support applications. The joint development agreement will see Orbita’s technology rolled out to digital health applications that enhance the patient experience and increase efficiency throughout the health continuum.

Orbita, a U.S.-based company, provides healthcare, life-science, and medical technology organizations with HIPAA-compliant chatbots and voice assistants for ‘digital front door’ applications, remote and in-facility patient support, pre- and post-visit outreach, and other healthcare applications. Its conversational platform allows developers and non-technical staff to quickly build and easily manage cloud-based virtual assistants that are seamlessly deployable to smart speakers, web and mobile chat apps, short message service (SMS) and interactive voice response (IVR) services, as well as custom devices.

“With the acceleration in the adoption of telehealth during the COVID-19 pandemic, AI-enabled voice services, virtual assistants and chatbots are already playing an enabling role in driving 24/7 access to healthcare, enhancing patient engagement, and improving clinical efficiency,” said Henk van Houten, Chief Technology Officer and Head of Philips Research. "Orbita is a not only a leader and innovator in voice and chat-powered virtual assistants that deliver the human touch needed in healthcare, but also a company that can keep up with the rapid pace of telehealth innovation that Philips is determined to pursue.”

“We are extremely excited to be expanding our partnership with Philips, one of the largest and most innovative digital health technology companies in the world,” said Nathan Treloar, President and Chief Operating Officer at Orbita. “Philips’ presence in the industry means they are at the forefront of healthcare’s most demanding challenges, where the greatest opportunities exist to apply the unique capabilities of Orbita’s products and solutions.”

Philips believes that AI has the potential to improve people’s lives across the health continuum – from healthy living and prevention to diagnosis, treatment, and home care – provided it is applied with a deep understanding of people's lives, and the clinical and operational context in which healthcare providers operate. Its partnership with Orbita, a company that has a proven track record of successfully applying AI-enabled conversational virtual assistants in healthcare applications, is part of Philips’ overall strategy to leverage cutting-edge AI wherever it can help deliver on the Quadruple Aim of healthcare. Examples where Philips is already using AI can be found in its offerings. Examples of Orbita’s solutions include , , and .

Philips owns a minority interest in Orbita through its Health Technology Venture Fund since May of 2020. Philips Health Technology Ventures manages a business-agnostic digital health fund that invests in, and partners with, promising healthcare informatics and health technology start-up companies to accelerate their growth and extend their reach. Active partnerships, such as the one announced today with Orbita, are an essential part of Philips’ goal to develop integrated solutions that enable healthcare providers to deliver on the Quadruple Aim – better health outcomes, better patient and staff experiences, and lower cost of care.

For further information, please contact:

For Philips:

Ben Zwirs

Philips Global Press Office

Tel.:

E-mail:

For Orbita Inc.:

Julia Searcy

MERGE

Tel.: +1  678.879.1929

E-mail:  

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at .

About Orbita Inc.

Orbita's award-winning, HIPAA-compliant conversational AI platform powers voice and chat solutions for healthcare and life sciences organizations that improve patient engagement, increase clinical efficiency, and improve outcomes. Customers include innovative organizations like Mass General Brigham, Mayo Clinic, Amwell, Yale New Haven Hospital, Cancer Treatment Centers of America, University of Chicago Medicine, and a portfolio of pharmaceutical clients. Partners include Cognizant, Deloitte, Pariveda, and ServiceNow. Find us at , contact us at .



EN
29/03/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips intends to extend maturity of forward purchases of 4 million s...

Philips intends to extend maturity of forward purchases of 4 million shares for long-term incentive plans September 15, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA) announces today that it intends to extend the settlement of two forward contracts for 2 million long-term incentive plans shares each as part of the share repurchase program on June 14, 2023. The planned extension will postpone the original maturity dates in Q4 2025 by one year to a new maturity date in Q4 2026. Further details will be available via this . For further information, please contact:Michael FuchsPhil...

 PRESS RELEASE

Philips and Masimo announce innovation partnership to advance access t...

Philips and Masimo announce innovation partnership to advance access to patient monitoring measurement technologies September 11, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, and (NASDAQ: MASI) today announced that the two companies have renewed their multi-year strategic collaboration, marking a fresh chapter in their long-standing partnership. With a shared commitment to innovation and expanding access to high-quality, connected care, the two companies are taking a bold new approach in accelerating the development and delivery of next-...

 PRESS RELEASE

Philips launches smart telemetry platform for cardiac monitoring that ...

Philips launches smart telemetry platform for cardiac monitoring that provides continuous, enterprise-wide connectivity beyond the bedside September 4, 2025 Empowering clinical teams to respond to surges, track usage and ease workflows with user-friendly touchscreen technology for telemetry patients on the move Cambridge, Massachusetts – , a global leader in health technology, today announced the introduction of an  designed to help address critical challenges in healthcare – including staff shortages and alarm management. A key component of the solution is the next-generation Telemetry M...

 PRESS RELEASE

Philips launches Transcend Plus for EPIQ CVx and Affiniti CVx, deliver...

Philips launches Transcend Plus for EPIQ CVx and Affiniti CVx, delivering breakthrough image quality and FDA-cleared AI enhancements in cardiovascular ultrasound August 27, 2025  Next-generation 2D and 3D imaging and intelligent automation empower clinicians to make faster, more confident decisions in cardiac care Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the release of Transcend Plus, the next generation its EPIQ CVx and Affiniti CVx cardiovascular ultrasound systems. Transcend Plus delivers major advancements in image qua...

Marc Hesselink ... (+3)
  • Marc Hesselink
  • CFA
  • Thymen Rundberg

Philips/Volatile results/HOLD

Philips reported a better-than-expected 2Q25 update. We increase our target price to €23 per share (from €21) but keep our Hold rating. The results are surprisingly volatile in our view with large quarterly fluctuations. We believe valuation is fair relative to peers given its lower growth and margin profile.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch